Nupur Nagarkatti
Postdoctoral AssociateAbout
Titles
Postdoctoral Associate
Appointments
Departments & Organizations
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Nupur Nagarkatti's published research.
Publications Timeline
A big-picture view of Nupur Nagarkatti's research output by year.
Alessandro Santin, MD
Natalia Buza, MD
Peter Schwartz, MD
Gloria Huang, MD, FACOG
Akiko Iwasaki, PhD
Pei Hui, PhD, MD
18Publications
189Citations
Publications
2023
Why Are There So Few Women Medical School Deans? Debunking the Myth That Shorter Tenures Drive Disparities
Gottlieb A, Roy B, Herrin J, Holaday L, Weiss J, Salazar M, Okoli N, Nagarkatti N, Otridge J, Pomeroy C. Why Are There So Few Women Medical School Deans? Debunking the Myth That Shorter Tenures Drive Disparities. Academic Medicine 2023, 99: 63-69. PMID: 37418698, DOI: 10.1097/acm.0000000000005315.Peer-Reviewed Original ResearchCitationsAltmetricAn Evaluation of Sex-Based Differences in Surrogate Consent for Older Adults Undergoing Surgical Intervention
Nagarkatti N, Miller S, Ahuja V, Schneider E, Mohanty S, Kodadek L. An Evaluation of Sex-Based Differences in Surrogate Consent for Older Adults Undergoing Surgical Intervention. Journal Of Surgical Research 2023, 288: 246-251. PMID: 37030182, DOI: 10.1016/j.jss.2023.02.041.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsPreoperative cognitive impairmentMale patientsCognitive impairmentSurrogate consentSurgeons National Surgical Quality Improvement ProgramNational Surgical Quality Improvement ProgramSurgical Quality Improvement ProgramPatients age 65Preoperative cognitive statusQuality Improvement ProgramHigh rateSex-based differencesFemale patientsPatient sexSurgical interventionStratified analysisFacets of medicineAge 75American CollegePatientsAge 65Cognitive statusDescriptive studyOlder adultsAge categories
2022
Do Cultures From Percutaneously Drained Intra-abdominal Abscesses Change Treatment? A Retrospective Review
Esposito A, Zhang Y, Nagarkatti N, Laird W, Coppersmith N, Reddy V, Leeds I, Mongiu A, Longo W, Hao R, Pantel H. Do Cultures From Percutaneously Drained Intra-abdominal Abscesses Change Treatment? A Retrospective Review. Diseases Of The Colon & Rectum 2022, 66: 451-457. PMID: 36538708, DOI: 10.1097/dcr.0000000000002644.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIntra-abdominal abscessPercutaneous drainAntimicrobial therapyLos pacientesAbdominal abscessSingle university-affiliated institutionRetrospective medical record reviewEmpiric antibiotic regimensSolid organ transplantsMedical record reviewUniversity-affiliated institutionCulture dataAntibiotic coursesAbdominal infectionAntibiotic regimensActive smokersMedian ageActive chemotherapyRecord reviewEvidence-based practiceMedian lengthUtility of cultureFemale sexIntraoperative culturesInclusion criteriaSurrogate consent for surgery among older adult patients
Miller SM, Nagarkatti N, Ahuja V, Schneider EB, Mohanty S, Rosenthal RA, Kodadek LM. Surrogate consent for surgery among older adult patients. Surgery 2022, 172: 1748-1752. PMID: 36123180, DOI: 10.1016/j.surg.2022.08.015.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHalf of patientsCognitive impairmentSurrogate consentHigher comorbidity burdenOlder adult patientsComorbidity burdenPreoperative disabilityAdult patientsOlder patientsFemale patientsSurgical interventionElective proceduresSurgical proceduresHealth characteristicsAmerican CollegeDaily livingOwn consentPatientsOlder adultsImpairmentSurgeryConsentDescriptive analysisFurther researchDiagnosisReal-world evaluation of safety and effectiveness of dydrogesterone in the management of threatened abortion
Nagarkatti R, Mehra D, Mandal S, Dhawan A, Joshi P, Nagarkatti N, Chinda M, Jaiswal A. Real-world evaluation of safety and effectiveness of dydrogesterone in the management of threatened abortion. International Journal Of Reproduction Contraception Obstetrics And Gynecology 2022, 0: 2096. DOI: 10.18203/2320-1770.ijrcog20221833.Peer-Reviewed Original ResearchCitationsConceptsLow back painOral dydrogesteroneBack painPregnancy lossRetrospective analysisReal-world retrospective analysisMain presenting symptomRelief of symptomsWeeks of gestationCase report formsTreatment of womenVaginal bleeding/Establishment of hemostasisDydrogesterone treatmentAbdominal painPresenting symptomTolerability profileAdverse eventsCommon complicationMedian timeEndogenous progesteroneFirst trimesterSurgical interventionBleeding/Case report
2021
Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites
Li JY, Mutlu L, Tymon-Rosario J, Khadraoui W, Nagarkatti N, Hui P, Buza N, Lu L, Schwartz P, Menderes G. Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites. Gynecologic Oncology Reports 2021, 39: 100913. PMID: 35005157, PMCID: PMC8715286, DOI: 10.1016/j.gore.2021.100913.Peer-Reviewed Original ResearchCitationsConceptsRecurrence-free survivalEarly-stage diseaseHigh-grade histologyOvarian preservationNode dissectionGrade histologyOncologic outcomesOverall survivalClinicopathologic characteristicsMyometrial invasionSarcomatous overgrowthPatients underwent lymph node dissectionUnderwent lymph node dissectionCox proportional hazards regressionLymph node dissectionEvidence of diseaseNon-inferior outcomesDeep myometrial invasionProportional hazards regressionLog-rank testKaplan-Meier estimatesLarge patient cohortPractical management optionsBilateral adnexectomyCervical adenosarcomaA phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability
Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon‐Rosario J, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability. Cancer 2021, 128: 1206-1218. PMID: 34875107, PMCID: PMC9465822, DOI: 10.1002/cncr.34025.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsObjective response rateImmune checkpoint inhibitorsProgression-free survivalEndometrial cancerWhole-exome sequencingSporadic endometrial cancerOverall survivalEnd pointPhase 2 pilot studyPrimary end pointSecondary end pointsTumor mutation burdenPhase 2 evaluationLarger confirmatory studiesAntigen processing/presentationProcessing/presentationCheckpoint inhibitorsSurgical resectionICI resistanceDMMR patientsPrognostic significanceDMMR tumorsMechanisms of resistanceLocal treatmentSporadic MSIDHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo
Tymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecologic Oncology 2021, 163: 334-341. PMID: 34452746, PMCID: PMC8722447, DOI: 10.1016/j.ygyno.2021.08.014.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBenzodiazepinesBystander EffectCell Line, TumorCystadenocarcinoma, SerousDrug Resistance, NeoplasmFemaleHumansImmunoconjugatesMiddle AgedPrimary Cell CultureReceptor, ErbB-2TrastuzumabUterine NeoplasmsXenograft Model Antitumor AssaysConceptsHER2/neuPrimary USC cell linesUSC cell linesUterine serous carcinomaSerous carcinomaHER2/Cell linesBystander killingHER2/neu protein expressionHER2/neu overexpressionProtein expressionNovel treatment optionsAggressive histologic variantNeu protein expressionHER2 protein expressionC-erbB2 gene amplificationSignificant bystander killingUSC xenograftsEndometrial cancerNegative tumorsPoor prognosisPositive tumorsTreatment optionsPreclinical activityHistologic variantsA phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
Roque D, Bellone S, Siegel E, Buza N, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Schwartz P, Ratner E, Alexandrov L, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin A. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Journal Of Clinical Oncology 2021, 39: 5523-5523. DOI: 10.1200/jco.2021.39.15_suppl.5523.Peer-Reviewed Original ResearchCitationsConceptsObjective response rateImmune checkpoint inhibitorsEndometrial cancer patientsTumor mutational burdenCancer patientsGrade 3/4 treatment-related adverse eventsSolid Tumors version 1.1Treatment-related adverse eventsSporadic tumorsPhase II pilot studyOverall survival proportionPrimary end pointResponse Evaluation CriteriaPhase II evaluationAntigen processing/presentationProcessing/presentationAdverse eventsICI resistancePrognostic significanceMechanisms of resistancePolymerase chain reactionII evaluationClinical studiesMutational burdenPatientsA phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)
Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin AD. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Annals Of Oncology 2021, 32: 1045-1046. PMID: 33932502, PMCID: PMC9465821, DOI: 10.1016/j.annonc.2021.04.013.Commentaries, Editorials and LettersCitationsAltmetricMeSH Keywords and Concepts